Overview

Effectiveness of ACS in Extreme Preemies

Status:
Withdrawn
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
This is a randomized prospective clinical study that will evaluate the effects of antenatal corticosteroid administration (ACS) vs. placebo in singleton pregnancies who are threatening to deliver prematurely between 22 0/7 and 23 6/7 weeks on admission with the goal of improving composite neonatal mortality and morbidity.
Phase:
Phase 3
Details
Lead Sponsor:
Mednax Center for Research, Education and Quality
Mednax Center for Research, Education, Quality and Safety
Treatments:
Betamethasone
Betamethasone benzoate
Betamethasone sodium phosphate
Betamethasone Valerate
Betamethasone-17,21-dipropionate